Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Cancer Research and Treatment|November 10, 2023
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in KoreaJi Yun Lee, Ji Hyun Kwon, Joon Young Hur, et al.
Annals of Hematology|July 1, 2023
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)Mihee Kim, Je-Jung Lee, Chang-Ki Min, et al.
Cancer Research and Treatment|March 7, 2024
Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913)Ho-Jin Shin, Do-Young Kim, Kihyun Kim, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2019
Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic SyndromeSungwoo Park, Dong Won Baek, Sang Kyun Sohn, et al.
Oncology Research and Treatment|October 17, 2025
Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell ActivityJae-Hyeog Choi, Saegwang Park, Xingguo Quan, et al.
American Journal of Hematology|January 11, 2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)Ho Sup Lee, Kihyun Kim, Seok Jin Kim, et al.
BMC Cancer|February 5, 2025
Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myelomaKa-Won Kang, Dae Sik Kim, Se Ryeon Lee, et al.
Leukemia Research|June 26, 2024
Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trialsDong-Yeop Shin, Sahee Park, Eunjung Jang, et al.
Nature Communications|March 30, 2024
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trialChanghee Park, Ho Sup Lee, Ka-Won Kang, et al.
Cancer Research and Treatment|July 16, 2024
Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC StudyYoon Seok Choi, Joonho Shim, Ka-Won Kang, et al.
Pageof 9